Literature DB >> 22403428

Performance of the novel Qiagen artus QS-RGQ viral load assays compared to that of the Abbott RealTime system with genetically diversified HIV and hepatitis C Virus plasma specimens.

Jan Felix Drexler1, Ulrike Reber, Andrea Wuttkopf, Anna Maria Eis-Hübinger, Christian Drosten.   

Abstract

We compared two novel Qiagen QS-RGQ viral load assays with the established Abbott RealTime assays on a highly diversified panel of 121 human immunodeficiency virus (HIV) and 107 hepatitis C virus (HCV) specimens. The quantifications correlated well for all HIV and HCV types, but Qiagen yielded higher HCV concentrations than Abbott, predominantly in genotypes 4 and 5.

Entities:  

Mesh：

Year:  2012        PMID： 22403428      PMCID： PMC3372116          DOI： 10.1128/JCM.05874-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  17 in total

1.  Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes.

Authors:  Marie Gueudin; Jean Christophe Plantier; Véronique Lemée; Marie Paule Schmitt; Loic Chartier; Thomas Bourlet; Annick Ruffault; Florence Damond; Muriel Vray; François Simon
Journal:  J Acquir Immune Defic Syndr       Date:  2007-04-15       Impact factor: 3.731

2.  Rates of and reasons for failure of commercial human immunodeficiency virus type 1 viral load assays in Brazil.

Authors:  Jan Felix Drexler; Luciano Kleber de Souza Luna; Celia Pedroso; Diana Brasil Pedral-Sampaio; Artur T L Queiroz; Carlos Brites; Eduardo M Netto; Christian Drosten
Journal:  J Clin Microbiol       Date:  2007-03-28       Impact factor: 5.948

3.  Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay.

Authors:  Marcel Beld; Roel Sentjens; Sjoerd Rebers; Christine Weegink; Jan Weel; Cees Sol; René Boom
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.

Authors:  M Schutten; D Peters; N K T Back; M Beld; K Beuselinck; V Foulongne; A-M Geretti; L Pandiani; C Tiemann; H G M Niesters
Journal:  J Clin Microbiol       Date:  2007-04-04       Impact factor: 5.948

5.  Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

Authors:  S C Lee; A Antony; N Lee; J Leibow; J Q Yang; S Soviero; K Gutekunst; M Rosenstraus
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

6.  Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy.

Authors:  N A Terrault; J-M Pawlotsky; J McHutchison; F Anderson; M Krajden; S Gordon; I Zitron; R Perrillo; R Gish; M Holodniy; M Friesenhahn
Journal:  J Viral Hepat       Date:  2005-09       Impact factor: 3.728

7.  Clinical performance of the new rRoche COBAS TaqMan HCV Test and High Pure System for extraction, detection and quantitation of HCV RNA in plasma and serum.

Authors:  Huub C r Gelderblom; Sandra Menting; Marcel G Beld
Journal:  Antivir Ther       Date:  2006

8.  HIV-1 viral load assays for resource-limited settings: clades matter.

Authors:  Wolfgang Preiser; Jan Felix Drexler; Christian Drosten
Journal:  PLoS Med       Date:  2006-12       Impact factor: 11.069

Review 9.  HIV-1 viral load assays for resource-limited settings.

Authors:  Susan A Fiscus; Ben Cheng; Suzanne M Crowe; Lisa Demeter; Cheryl Jennings; Veronica Miller; Richard Respess; Wendy Stevens
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

10.  Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences.

Authors:  Donald G Murphy; Bernard Willems; Marc Deschênes; Nir Hilzenrat; Roger Mousseau; Sidney Sabbah
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948
View more
  5 in total

1.  Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors.

Authors:  F Wiesmann; G Naeth; C Sarrazin; A Berger; R Kaiser; R Ehret; H Knechten; P Braun
Journal:  Med Microbiol Immunol       Date:  2014-11-15       Impact factor: 3.402

2.  Electrochemical Biosensor for Sensitive Detection of Hepatitis B in Human Plasma.

Authors:  Ana Cristina Honorato de Castro; Leandro Toshio Kochi; José Manuel Rodrigueiro Flauzino; Márcia Maria Costa Nunes Soares; Valéria Almeida Alves; Luís Antônio da Silva; João Marcos Madurro; Ana Graci Brito-Madurro
Journal:  Appl Biochem Biotechnol       Date:  2022-02-19       Impact factor: 2.926

Review 3.  Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging.

Authors:  Verónica Saludes; Victoria González; Ramon Planas; Lurdes Matas; Vicente Ausina; Elisa Martró
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 4.  Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies.

Authors:  Bryan Cobb; Gabrielle Heilek; Regis A Vilchez
Journal:  BMC Infect Dis       Date:  2014-09-05       Impact factor: 3.090

Review 5.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Mamun Al-Mahtab; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-05-26       Impact factor: 6.047
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.